David Solomon

Directeur Général chez THALIA THERAPEUTICS PLC

Profil

David Horn Solomon is currently Chief Executive Officer at Sanmirna Therapeutics, Inc. Former roles include Chief Executive Officer & Director at Silence Therapeutics Plc from 2018 to 2020, Chief Executive Officer & Director at Pharnext SA from 2020 to 2022, Chief Executive Officer at Mithra Pharmaceuticals SA from 2023 to 2024, Chief Executive Officer at Akari Therapeutics Plc from 2017 to 2018, President & Chief Executive Officer at Zealand Pharma A from 2009 to 2015, President & Chief Executive Officer at Bionor Pharma ASA from 2015 to 2016, Executive Chairman at Promosome LLC from 2016 to 2017, Non-Executive Chairman at Advicenne SA from 2019 to 2022, Chief Operating Officer at Vital Sensors Holding Co., Inc. from 2006 to 2008, Chief Scientific Officer at Critical Care Diagnostics, Inc. in 2006, Chief Scientific Officer at Remedy Pharmaceuticals, Inc. in 2006, Managing Partner at Sund Capital ApS from 2016 to 2018, Independent Director at Sangamo Therapeutics France SAS from 2014 to 2018, Director at Valerio Therapeutics SA from 2011 to 2012, and Managing Director at Silence Therapeutics GmbH.
Other positions include Chairman at Solomons Ltd. and Ixaka Ltd., Director at American Chamber of Commerce In Denmark and The Cass Foundation, and Professor-Pharmacology & Neurology at Columbia University College of Physicians & Surgeons.
Education includes a doctorate from Weill Cornell Medical College conferred in 1991.

Postes actifs de David Solomon

Sociétés	Poste	Début
THALIA THERAPEUTICS PLC	Directeur Général	24/02/2026

Anciens postes connus de David Solomon

Sociétés	Poste	Fin
MITHRA PHARMACEUTICALS S.A.	Directeur Général	05/03/2024
PHARNEXT SCA	Directeur Général	27/11/2022
ADVICENNE	Président	09/06/2022
SILENCE THERAPEUTICS PLC	Directeur Général	01/01/2020
TXCELL	Directeur/Membre du Conseil	01/11/2018